CSPC Pharmaceutical Group Limited
Fair Pricing Policy

Chapter I General Provisions

Article 1 To regulate the pricing behaviour of drugs and related products of CSPC Pharmaceutical Group Limited and its subsidiaries (hereinafter collectively referred to as the "Group"), enhance drug accessibility, prevent price compliance and reputation risks, and safeguard the legitimate rights and interests of the Group, patients, and other relevant parties, this Policy is formulated in accordance with relevant laws, regulations, and industry norms, and in light of the actual situation of the Group.

Article 2 "Fair pricing" as referred to in this Policy means that, under the premise of legal compliance, the Group comprehensively considers objective factors such as the economic development levels, healthcare systems, patients' ability to pay, market environments, and product characteristics of different countries and regions, to form a reasonable, explainable, and traceable pricing arrangement.

Article 3 This Policy applies to the decision-making, management, and execution activities related to product pricing carried out by the Group and its subsidiaries both domestically and overseas.

Chapter II Management Body

Article 4 The Board of Directors of the Group bears ultimate responsibility for the formulation and implementation of the Fair Pricing Policy, and supervises and guides related major matters. The Government Affairs and Market Access Department and various branches and subsidiaries are responsible for the management and execution of relevant matters.

Chapter IV Management and Control Content

Article 5 The Group's pricing management shall follow the principles of legal compliance, adaptation to local conditions, fairness and reasonableness, and prudence and transparency, balancing commercial sustainability with drug accessibility, and avoiding any form of unfair pricing behaviour.

Article 6 When conducting pricing management, the Group attaches great importance to the impact of drug prices on patients' medication burden. Under the premise of legal compliance and commercial sustainability, and taking into account factors such as the economic development levels, medical insurance conditions, and patients' ability to pay in different countries and regions, the Group prudently evaluates pricing schemes. The Group actively supports reducing patients' medication burden and enhancing drug accessibility through reasonable pricing, alignment with medical insurance policies, and other compliant methods.

Article 7 In the pricing decision-making process, the Group may comprehensively consider product types, product lifecycles, the situation of similar products in the market, public health needs, and other relevant factors. The Group shall make prudent decisions through internal management procedures to prevent compliance and reputation risks.

Article 8 In enhancing drug accessibility, the Group encourages the lawful and compliant use of various methods, such as price management and fund support, to promote more affordable medication options for patients, provided that fair competition and compliance requirements are not compromised.

Article 9 The Group strictly prohibits any pricing behaviour that violates national laws, regulations, and the requirements of this Policy, including but not limited to price manipulation, price collusion, abuse of market dominance, or the improper transfer of benefits through pricing arrangements.

Chapter V Supplementary Provisions

Article 10 For matters not covered by this Policy, or in the event of any conflict with relevant laws and regulations, the relevant provisions of such laws and regulations shall prevail.

Article 11 This Policy shall be interpreted by the Government Affairs Department of the Group and shall come into effect on the date of review and approval by the Board of Directors of the Group.